In primary AML cells, combining the MCL-1 inhibitor S63845 with VEN results in greater efficacy than either inhibitor alone, with a more potent activity against leukemic rather than normal hematopoietic progenitors68. The gene discussed is MCL1; the disease is acute myeloid leukemia.